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Abstract
Schizophrenia is a severe, debilitating, chronic disease that is accompanied by morphologic changes within
the brain. However, it is unclear to what extent alterations of grey and white matter in schizophrenia are linked
to the disease itself, or whether they are a consequence of neuroleptic treatment. Typical and atypical antipsycho-
tics exert differential effects on brain structure. Moreover, atypical antipsychotics may have distinct proﬁles with
respect to grey matter in schizophrenic patients. Findings on drug-induced grey matter changes are hetero-
geneous due to variation in stage of illness, duration of treatment and use of multiple antipsychotics. Using
voxel-based morphometry applied to high-resolution magnetic resonance images, we show that monotherapy
with the atypical agent quetiapine (mean daily dose=445mg±200 S.D.) may induce structural brain changes in
ﬁrst-episode schizophrenia patients (N=20) within 21 d of treatment. Speciﬁcally, we demonstrate longitudinal
macroscopic changes (i.e. grey matter increases) in the left amygdalohippocampal region that were predicted
by drug plasma levels but not daily doses. These structural alterations were accompanied by a clinical improve-
ment of schizophrenic symptoms. Comparison with healthy controls (n=30) showed that grey matter amount
in the respective amygdalar region was signiﬁcantly reduced in unmedicated ﬁrst-episode schizophrenia
patients. These ﬁndings suggest that drug-induced neuroplastic changes in schizophrenia can occur quickly
and are dependent on pharmacokinetics.
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Introduction
Schizophrenia is a brain disorder with multifactorial
aetiology. Environmental risk factors such as urbanicity
(McGrath et al., 2004; Krabbendam and van Os, 2005)
and genetic components (see work by Rodriguez-Murillo
et al. (2012) for an overview) may interact with altered
brain function in schizophrenia patients. In particular,
amygdala function is likely inﬂuenced by such extrinsic
and intrinsic factors (Cousijn et al., 2010; Lederbogen
et al., 2011). However, dysfunctional amygdala activity
in schizophrenia patients is related to clinical state rather
than to genetic predisposition (Rasetti et al., 2009).
In addition to functional abnormalities, a broad
range of structural alterations has been demonstrated in
patients with schizophrenia. Also, structural abnormalities
of the amygdala–hippocampus complex have been found
to be associated with psychopathology (Rajarethinam
et al., 2001; Tomasino et al., 2011). In general, the neuro-
anatomical changes in schizophrenia are by no means
static but progress with the disease, as revealed by a re-
cent meta-analysis (Chan et al., 2011). Reviewing 41
voxel-based morphometry (VBM) studies, Chan and col-
leagues found strong evidence that in patients suffering
from a ﬁrst episode of schizophrenia, the fronto-temporal,
striatal and cerebellar grey matter (GM) amount is lower
than in individuals at high risk for schizophrenia.
Furthermore, disease progression from the ﬁrst episode
to chronic schizophrenia was shown to be associated
with GM decrease in the anterior cingulate cortex
(ACC), right insula, left amygdala and thalamus. Thus,
the authors summarized that schizophrenia seems to
represent a progressive cortico-striato-thalamic loop dis-
order. In addition, the results may also be seen as consist-
ent with the notion of schizophrenic ‘cognitive dysmetria’
due to a dysfunctional prefrontal-thalamic-cerebellar
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circuitry (Andreasen et al., 1996; Andreasen, 1999).
Another recent meta-analysis (Olabi et al., 2011), speciﬁ-
cally focusing on longitudinal volumetric studies using
region-of-interest structural magnetic resonance imaging,
suggested that potential schizophrenia-related alterations
in the amygdala–hippocampus complex are not progress-
ive. However, it revealed signiﬁcantly greater decreases
in frontal grey and white matter, parietal white matter
and temporal white matter volume over time in schizo-
phrenia patients compared with healthy controls.
This provides evidence of progredient GM changes
in schizophrenia, but leaves a critical question unclear:
whether these changes are related to the disease itself
or rather attributable to medication. While there is con-
sensus that treatment with antipsychotics affects brain
structure, the relationship between type of medication
and neuroanatomical location still remains a matter of de-
bate. Initially, an increased volume of the basal ganglia,
particularly the caudate nuclei, following antipsychotic
treatment has been described (Chakos et al., 1994).
Subsequent studies indicated differential effects of
typical and atypical agents. Typical agents were assumed
to increase basal ganglia GM, whereas atypicals seemed
to reverse such effects (Gur et al., 1998; Corson et al.,
1999; Smieskova et al., 2009). In addition, treatment
with atypical neuroleptics has been found to lead to
GM increase in the thalamus (Gur et al., 1998; Tomelleri
et al., 2009). However, the absence of GM changes follow-
ing atypical neuroleptic treatment has also been reported
(McClure et al., 2008). This may be explained by distinct
neuroplastic or neurotoxic effects of different drugs.
Different atypical antipsychotics appear to exhibit speciﬁc
effects on brain structure. Increases of GM in the caudate
and nucleus accumbens, in the superior temporal gyrus
(STG) and in the parietal as well as the occipital lobes
have been described after treatment with risperidone
(Massana et al., 2005; Molina et al., 2005; Girgis et al.,
2006), and a decrease in the basal ganglia and an increase
in the orbitofrontal cortex (OFC) and ACC after treatment
with quetiapine (Stip et al., 2008, 2009). However, even
with the same compound, conﬂicting results emerged:
olanzapine, for instance, has been reported to leave GM
unaffected (Lieberman et al., 2005) but also to be asso-
ciated with GM decrease in the frontal and parietal
regions (Molina et al., 2007). In summary, there is a con-
siderable variability in magnetic resonance imaging
data in schizophrenia (Honea et al., 2005). With respect
to drug-induced structural brain alterations, differential
effects between the typical and atypical antipsychotic
groups seem to provide only a partial explanation of
this variability. Hence, the categorization into typical
and atypical antipsychotics may represent an over-
simpliﬁcation in this regard.
Synopsis and interpretation of these heterogeneous
ﬁndings are complicated by the involvement of different
patient samples (e.g. ﬁrst-episode vs. chronic schizo-
phrenia patients), uneven duration of treatment, small
sample sizes and the employment of a priori hypotheses
deduced from previous neuro-imaging studies in schizo-
phrenia, which may have led to bias. This implies a strong
need for further prospective investigations of longitudinal
GM changes associated with antipsychotics, at best ac-
counting for drug-dependent variability in neuroplastic
effects.
Hence, the present work sought to explore whether an
atypical antipsychotic, quetiapine, is capable of inducing
neuroplastic changes in unmedicated patients with ﬁrst-
episode schizophrenia. Placebo-controlled studies have
shown that clinical improvement may be expected within
2–3wk of quetiapine treatment (Buckley, 2004). Accor-
dingly, we hypothesized that quetiapine-related neuro-
plastic changes, possibly linked to symptom reduction,
would likewise be traceable after such a time period.
Based on preclinical literature pointing to a neuroplastic
effect of quetiapine on the amygdalohippocampal com-
plex (Xu et al., 2002; Fumagalli et al., 2004; Luo et al.,
2005; Park et al., 2006), it seemed likely that changes
would also occur in this region in schizophrenia patients.
Method
Subjects
Forty-three patients with a suspected ﬁrst episode of
schizophrenia according to both DSM-IV-TR (American
Psychiatric Association, 2000) and ICD-10 (World
Health Organization, 1994) were included. Patients had
been screened according to the following criteria: in-
cluded were female and male patients aged from 18 to
65 yr with no history of previous intake of antipsychotics.
Female patients of childbearing age had to be on secure
contraception, and gravidity was excluded by a preg-
nancy test. Patients fulﬁlling the criteria of any other
psychiatric disorder than schizophrenia, especially drug-
induced psychosis, and suicidal patients were excluded.
Furthermore, patients with a known history of intake of
antipsychotics, an intolerance of quetiapine fumarate, or
the concomittant intake of cytochrome P450 inductors/
inhibitors or psychotropic medication (e.g. antidepres-
sants, anticonvulsants, etc.) except for hypnotics and
benzodiazepines, were non-eligible. Special care was
taken during the whole trial to ensure that exclusion cri-
teria were not violated and that patients were treated
with quetiapine monotherapy. In the case of necessity
of indispensable co-medication, the patient was excluded.
In addition, quetiapine plasma levels were measured at
baseline assessment to eliminate the possibility that
patients had recently taken quetiapine (contrary to their
claims). Moreover, patients suffering from an unstable
somatic comorbidity, with epilepsy, brain malformation,
history of traumatic brain injury, an absolute neutrophil
count <1.5×109 l−1 or an HbA1c value >8.5% were
excluded. Finally, patients who had taken part in another
clinical trial within the last 30 d before screening were not
included in the study.
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All patients provided written informed consent to
participate in the study (ClinicalTrials.gov Identiﬁer:
NCT00554658). The protocol was approved by the local
ethics committee and was therefore in accordance with
the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. Four patients
dropped out between screening and baseline assessment
(i.e. before quetiapine intake) due to acute worsening of
their psychopathological symptoms or a panic attack in
the MRI scanner. Another nine patients had to be taken
out of the trial after baseline assessment because of come-
dication (N=2, duloxetine/perazine), side effects (N=2),
drug noncompliance (N=1), revocation of consent form
(N=2) or loss of contact with the patient (N=2). After
end of treatment, another ten patients had to be excluded
due to diagnoses other than schizophrenia. Diagnoses in-
cluded adjustment disorder, acute and transient psychotic
disorder, bipolar affective disorder, depressive episode,
disturbance of activity and attention, emotionally instable
personality disorder, harmful use of cannabinoids, mixed
personality disorder, obsessive–compulsive disorder and
schizoaffective disorder. The characteristics (before and
after treatment) of the remaining 20 patients suffering
from a ﬁrst episode of schizophrenia are given in Table 1.
Thirty healthy and medication-free subjects served as a
comparison group and were matched for age and gender
to the patients. Mean age was 30.20±7.61 y (t=1.15, df=48,
p=0.258), the proportion female/male was 11/19 (χ2=0.75,
df=1, p=0.386). Inclusion of these controls was speciﬁcally
intended for testing whether the potential GM changes
after quetiapine intake were observed in regions altered
in ﬁrst-episode schizophrenia patients when compared
with healthy subjects.
Image acquisition
Structural magnetic resonance imaging at baseline
and follow-up was performed on a 1.5 T scanner
(MAGNETOM Sonata, Siemens Medical Solutions,
Germany), yielding T1 weighted, high-resolution brain
images. A 3D magnetization-prepared rapid acquisition
with gradient echo sequence was adopted: repetition
time 1880ms, echo time 3.42ms, ﬂip angle 15°, matrix
size 256×256, 176 sagittal slices, voxel size 1mm×1mm×
1mm. Data were analysed by means of VBM8 (http://
dbm.neuro.uni-jena.de/vbm/), integrated as a toolbox into
SPM8 (Wellcome Trust Centre for Neuroimaging, UK).
Image processing
To assess GM changes over time, the default longitudinal
preprocessing approach implemented in the VBM8 tool-
box was applied. After registration of the follow-up
image to the baseline image for each subject separately,
intra-subject bias correction was applied. Then, images
were segmented into different tissue classes, followed
by afﬁne (i.e. linear) and non-linear registration (i.e.
Dartel (Ashburner, 2007)) of the segments. The segment
approach is based on a maximum a posteriori (MAP) tech-
nique (Rajapakse et al., 1997) and employs a partial vol-
ume estimation (PVE (Tohka et al., 2004)). Moreover,
a spatially adaptive non-local means (SANLM) ﬁlter
(Manjón et al., 2010) and a classical Markov Random
Table 1. Patients’ (n=20) characteristics
Baseline Follow-up df t value p value
Age (y) 27.75±7.10
Sex: female/male 5/15
Treatment duration (d) 21.40±4.83
Cumulative quetiapine dose (mg) 9308.75±4055.08
Daily quetiapine dose (mg) 444.50±199.99
Quetiapine level (n=19) (ng/ml) 331.05±288.31
CGI-I 2.55±1.23
GAF 43.40±11.25 53.80±11.62 19 3.62 0.002
BPRS: Total score 54.65±12.52 45.85±16.16 19 2.87 0.010
PANSS: Total score 95.10±19.36 84.30±24.21 19 1.98 0.062
PANSS: Positive syndrome 21.65±5.17 17.80±5.13 19 3.15 0.005
PANSS: Negative syndrome 26.50±5.73 24.00±6.22 19 1.83 0.084
PANSS: General psychopathology 46.95±11.01 42.50±15.07 19 1.27 0.221
Values are given as mean±S.D.
Degrees of freedom (df), t and p values correspond to a paired t test on the scales for Global Assessment of Functioning (GAF)
(Caldecott-Hazard and Hall, 1994), Brief Psychiatric Rating (BPRS) (Overall and Gorham, 1962), and Positive and Negative
Syndrome (PANSS) (Kay et al., 1987) performed in SPSS (PASW Statistics 18, release version 18.0.0, SPSS, Inc., 2009, USA, http://
www.spss.com). CGI-I, Clinical Global Impression Improvement (Guy, 1976).
‘Baseline’ was deﬁned as the time-point of magnetic resonance imaging (MRI) on the day of ﬁrst administration of quetiapine; imaging
was performed before quetiapine intake. ‘Follow-up’ was deﬁned as the time-point of the MRI scan performed after treatment with
quetiapine; imaging was also performed before quetiapine intake. One patient’s quetiapine level data were lost.
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Field (MRF) approach (Rajapakse et al., 1997) were
used for denoising. Finally, the realigned and nor-
malized GM segments were smoothed using an isotropic
Gaussian kernel of 8 mm full width at half maximum
(FWHM). Similarly, for group comparisons, images
were registered using afﬁne and non-linear registration
(Ashburner, 2007) and segmented into three tissue
types. Also here, segmentation was reﬁnded by PVE,
a SANLM ﬁlter and a MRF approach (Rajapakse et al.,
1997; Tohka et al., 2004; Manjón et al., 2010). The modu-
lated GM images were then smoothed with an isotropic
Gaussian 8mm FWHM kernel.
Statistical analysis
The resulting (longitudinal) GM images were entered into
a repeated measures ANOVAwith the factors subject and
time (baseline and follow-up) to test for GM decreases
and increases following 3wk of antipsychotic treatment.
Firstly, we applied an uncorrected cluster-forming thres-
hold of p<0.001 to the resulting t-maps to maintain
high sensitivity to longitudinal structural brain changes.
To eliminate minor, presumably incidental, ﬁndings,
only clusters exceeding the number of expected voxels
according to the random ﬁeld theory (Worsley et al.,
1992) were reported at this threshold.
In a second step we investigated the relationship
between quantitative parameters of quetiapine treatment
and GM changes. To this end, baseline images were
subtracted from follow-up images for each participant, re-
spectively. The difference images were then fed into sep-
arate multiple regression analyses on the regressors
‘cumulative quetiapine dose’, ‘daily quetiapine dose’
and ‘quetiapine plasma level’. Each patient’s ‘cumulative
quetiapine dose’ was calculated by summing up the
doses of every single day, and ‘daily quetiapine dose’
in turn by dividing ‘cumulative quetiapine dose’ by the
number of days between baseline and follow-up assess-
ment. The regression analysis was restricted to the clus-
ters showing signiﬁcant GM change (i.e. clusters in
Table 2) according to the previously computed ANOVA
(inclusive masking, p<0.05). We then tested whether the
observed GM increases related to quantitative quetiapine
parameters were signiﬁcant using a small volume correc-
tion (SVC) with a sphere of 6mm diameter (centred at
the local maximum within the respective cluster) on a
statistical threshold of p<0.05, FWE corrected (Worsley
et al., 1996). Cluster correlation coefﬁcients (Pearson’s r)
were calculated by means of SPSS (PASW Statistics 18, re-
lease version 18.0.0, SPSS, Inc., 2009, USA, http://www.
spss.com) after extracting data based on the regression
design matrix with MarsBar (Brett et al., 2002).
Third, we compared grey matter of ﬁrst-episode
schizophrenia patients at baseline and of healthy controls
in two-sample t-tests to assess whether the longitudinal
GM changes occurred in regions altered in schizophrenia
patients. Similarly to the approach regarding quantitative
quetiapine parameters, this analysis was restricted
Table 2. Grey matter (GM) decreases and increases during antipsychotic treatment in ﬁrst-episode schizophrenia
Laterality Macroanatomical region
Cytoarchitectonic
region
Cluster size
in voxels
MNI coordinates
Z scorex y z
GM decreases
R Cerebellum, Lobule VIIa Crus I (Hem)
Cerebellum, Lobule VIIa Crus II (Hem)
1117 39 −66 −38 4.55
L Cerebellum, Lobule VIIa, Crus I (Hem)
Cerebellum, Lobule VI (Hem)
285 −33 −64 −36 3.93
R Inferior frontal gyrus (VLPFC) BA 47 69 30 27 −12 3.65
GM increases
R Cerebellum, Lobule VIIa Crus I (Hem)
Cerebellum, Lobule VIIa Crus II (Hem)
301 52 −57 −45 4.54
L Parahippocampal gyrus Amyg (LB)
Hipp (EC)
275 −28 −1 −33 4.19
R Temporal pole BA 38 133 21 10 −45 4.42
R Superior temporal gyrus (STG) TE 1.0 60 52 −16 −2 4.18
R Thalamus (Th-Prefrontal/Temporal) 50 12 −10 10 3.53
Thresholded at a voxelwise uncorrected p<0.001 with a cluster size k546 voxels (number of expected voxels according to the random
ﬁeld theory).
Amyg (LB), Amygdala (laterobasal); BA, Brodmann area; Hipp (EC), Hippocampus (entorhinal cortex); L, left; MNI, Montreal
Neurological Institute; R, right; VLPFC, ventrolateral prefrontal cortex.
Detailed information on cerebellar and cyto-architectonics is available for: EC, LB (Amunts et al., 2005), Th-Prefrontal, Th-Temporal
(Behrens et al., 2003), Lobule VIIa Crus I/II (Diedrichsen et al., 2009), and TE 1.0 (Morosan et al., 2001).
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to the clusters showing longitudinal GM change in the
schizophrenia patients; likewise, SVC was used, and the
statistical threshold was set to p<0.05, FWE corrected.
A reference image at an optimum threshold was cre-
ated from all available baseline and follow-up images,
serving as an explicit mask in all analyses (Ridgway
et al., 2009). Due to the non-isotropic smoothness of
VBM data, correction for non-stationarity was applied.
We chose VBM since it allows for assessment of grey
matter in whole-brain analyses in a rapid and automated
manner. However, we are aware that, although VBM
results may be compatible with and extend the ﬁndings
of volumetric ROI analyses (Job et al., 2002), VBM does
not make manual ROI-based analyses redundant. As
both methods may provide complementary information,
especially in the context of schizophrenia (Giuliani
et al., 2005), future volumetric ROI analyses based on
the results of the present study are recommended.
Anatomical labeling
Resulting brain regions were macroanatomically and
cytoarchitectonically labeled by means of the Anatomy
Toolbox (Eickhoff et al., 2005, 2006, 2007), assigning
GM changes to the most probable histological area.
Areas not included with the Anatomy Toolbox were
labeled by reference to the Talairach Daemon (Lancaster
et al., 2000). We report this probabilistic and histology-
based anatomical allocation in Table 2 and provide refer-
ences to details of the cytoarchitecture in the table note.
Results
Both CGI-I ratings obtained at follow-up and an increase
of GAF scores (p<0.01) indicated an average symptom
improvement from baseline to follow-up. A mean de-
crease of BPRS total scores also reached signiﬁcance
(p<0.05), whereas improvement according to PANSS
total scores was only observed as a trend (p<0.1).
Nevertheless, there was a signiﬁcant decrease of scores
on the positive syndrome subscale (p<0.01) (see Table 1
for details).
VBM differentiated several decreases and increases
of GM in schizophrenia patients following 3 wk of treat-
ment with quetiapine (cf. Table 2). GM reduction was
found in the cerebellum in both hemispheres as well
as in the right ventrolateral prefrontal cortex (VLPFC;
Brodmann area (BA) 47). An increase of GM amount
was observed in the right cerebellum (distinct from the
cluster showing decrease), thalamus, STG and temporal
pole (p<0.001, uncorrected).
Regression analysis revealed no signiﬁcant positive
or negative relationship between cumulative quetiapine
dose or average daily quetiapine dose with GM increases
or decreases in any brain region. In contrast, quetiapine
plasma level correlated positively with GM increase in
the amygdalohippocampal cluster, in particular the
laterobasal amygdalar subdivision (peak voxel coordi-
nates in Montreal Neurological Institute (MNI) space,
cluster size k in voxels: x=−22, y=−3, z=−26, k=59). SVC
indicated that quetiapine level-related GM increase in
the amygdala was signiﬁcant on voxel level (pSVC<0.05,
FWE corrected) (cf. Fig. 1). The corresponding cluster r
was 0.493 (see Fig. 2 for a scatter plot). No signiﬁcant
positive or negative relationship between quetiapine
plasma level with GM increases or decreases was found
in any other brain region.
The comparison of schizophrenia patients with healthy
controls revealed that GM amount in the laterobasal
amygdala was signiﬁcantly reduced in schizophrenia
patients before quetiapine treatment (x=−22, y=−3,
z=−23, k=93; pSVC<0.05, FWE corrected). This analysis
also showed that GM in the right (lobule VIIa, crura I
and II) and left (lobule VIIa, crus I; lobule VI) cerebellum,
both regions where longitudinal substance loss was
observed, had already signiﬁcantly been impaired in
schizophrenia patients at baseline (x=39, y=−58, z=−36,
k=546 and x=−27, y=−63, z=−32, k=278; pSVC<0.05,
FWE corrected). No areas of increased GM amount com-
pared to healthy controls were found in schizophrenia
patients.
Discussion
This is the ﬁrst study to demonstrate longitudinal GM
changes in ﬁrst-episode schizophrenia after neuroleptic
monotherapy within only 3wk. These structural altera-
tions indicate highly dynamic neural processes at the in-
itial stage of schizophrenia after initiation of neuroleptic
treatment with quetiapine. There is evidence that GM
changes induced by quetiapine after 5 months of treat-
ment correlate with changes in clinical condition (Stip
et al., 2009; Ebdrup et al., 2010). It is intriguing that struc-
tural brain changes related to treatment with quetiapine
can already be detected within 21 d. This time period is
in line with the onset of action of antipsychotics in the
treatment of psychoses (Agid et al., 2003; Leucht et al.,
2005, 2007; Zedkova et al., 2011). Thus, our results further
support the notion that neuroplasticity at a structural
level may be involved in mediating clinical improvement
(May et al., 2006).
In summary, we observed longitudinal GM increase
in the amygdalohippocampal region that correlated
with drug plasma levels and GM decrease bilaterally in
the cerebellum without a relationship with quantitative
drug parameters. Both changes occurred in areas showing
reduced GM in unmedicated schizophrenia patients com-
pared with healthy controls, according to a baseline brain
scan. The progressive GM loss in the cerebellum observed
after 3 wk is in line with the most recent quantitative
meta-analysis of structural brain changes in schizo-
phrenia linked to illness progression (Chan et al., 2011).
This study indicated a convergence of GM reduction
foci in the right hemisphere of the cerebellum when
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comparing ﬁrst-episode schizophrenia patients with
healthy controls. Furthermore, it suggested a decrease
of GM in the left cerebellum advancing with transition
of the disease from the ﬁrst episode to a chronic stage.
Here, we found no relationship of the longitudinal struc-
tural changes in the cerebellum with quantitative quetia-
pine parameters. The comparison with healthy controls
revealed GM reductions in right and left cerebellar struc-
tures in unmedicated, ﬁrst-episode schizophrenia
patients. Both ﬁndings suggest that GM loss in these
areas is linked to the disease (progress) rather than to
drug treatment. In this context, the trend of GM increase
in another distinct area in the cerebellum seems puzzling.
This ﬁnding may suggest regionally selective effects of
quetiapine on brain structure, and is in line with the
s
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Fig. 1. Grey matter (GM) increase in the left amygdala positively correlated with patients’ quetiapine levels. GM increase is
superimposed on sagittal, coronal and axial slices of an average standard brain. The left column shows the whole brain, whereas
the right column displays a part of the same slice at 3×magniﬁcation. A, anterior; I, inferior; P, posterior; S, superior.
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Fig. 2. Scatter plot of the relationship between the mean cluster
grey matter increase and quetiapine plasma level obtained at
follow-up. Pearson’s r=0.493, p<0.05 (two-sided).
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results of Deng et al. (2009), who found progrediently
increasing GM during treatment with various antipsycho-
tics in the cerebellum. Caution is warranted, however, as
we observed no relationship between cerebellar changes
and quantitative quetiapine parameters.
Apart from the cerebellum, structural GM alterations
related to illness progress have also been reported by
the respective meta-analysis in several other areas
(Chan et al., 2011). Thus, longitudinal GM reductions in
the cerebellum in ﬁrst-episode schizophrenia patients
without previous regular intake of antipsychotics point
to the importance of these structural alterations, parti-
cularly at the initial stage of the disease. The observation
that these GM changes occur as early as within 3 wk
underlines the rapidity of neuroanatomical changes in
both regions. Notably, the cerebellar area where patients
in our study exhibited GM loss (lobule VII, crus I/II)
corresponds to the cognitive region of the cerebellum
(Stoodley and Schmahmann, 2009). Considering emerg-
ing evidence for the role of the cerebellum (Stoodley,
2012) in cognition and known structural abnormalities
of this region in schizophrenia patients (Andreasen and
Pierson, 2008; Kühn et al., 2012), the observed GM loss
in these regions may reﬂect cognitive impairment in
schizophrenia.
GM deﬁcits of the left amygdala, as observed in the
present sample of ﬁrst-episode patients compared with
healthy controls, are in accord with VBM studies asses-
sing GM alterations in schizophrenia. More speciﬁcally,
such structural changes are consistently seen in indivi-
duals at high risk for schizophrenia, as well as at the
initial and chronic stages of the disease (Chan et al.,
2011). Generally, amygdala pathology in schizophrenia
seems to be lateralized to the left hemisphere ( Joyal
et al., 2003; Leung et al., 2011). Quetiapine might be
able to reverse these GM deﬁcits of the left amygdala,
as indicated by the observed GM increase after 3 wk of
treatment and the positive correlation between quetiapine
plasma levels and the degree of increase. The observation
that there was a relationship between GM change and
quetiapine plasma levels, but not doses, is not surprising,
given the only weak relationship between dose and
plasma concentration of quetiapine (Wittmann et al.,
2010; Sparshatt et al., 2011). Besides increasing amygdala
GM, patients also showed an improvement of (parti-
cularly positive) symptoms. The observed structural
changes might represent a basis for known relatedness
of amydala activity in schizophrenia to clinical state
(Rasetti et al., 2009).
Nevertheless, the value of quetiapine plasma concen-
tration monitoring in clinical practice is still considered
controversial (Mauri et al., 2007). While some authors
doubt its usefulness in the context of clinical routine
(Sparshatt et al., 2011), others argue in favour of measur-
ing quetiapine levels to optimize individual pharma-
cotherapy (Wittmann et al., 2010). The only weak
relationship of dose with plasma levels might at least
partly be explained by differences in individual clearance
and polymorphisms in the ABCB1 gene (Wittmann
et al., 2010; Nikisch et al., 2011). This gene encodes the
P-glycoprotein transporter (P-gp), which in turn may
inﬂuence both the blood and brain drug concentrations
(Nikisch et al., 2011). In general, high D2 receptor occu-
pancy during pharmacotherapy is positively correlated
with clinical improvement in schizophrenia (Yilmaz
et al., 2012). This may also hold true for quetiapine
(Pávics et al., 2004), but the relationship between quetia-
pine plasma level and D2 occupancy seems not entirely
clear (Sparshatt et al., 2011). Therefore, it has been sug-
gested that further research on the relationship between
quetiapine plasma concentration and clinical response
is necessary (Sparshatt et al., 2011). The observed depen-
dence of GM increase in the amygdala on quetiapine
plasma levels, together with the concomitance of these
structural brain changes with clinical improvement,
may provide an indirect argument for the relevance of
quetiapine plasma levels for clinical outcome.
The entorhinal cortex, located adjacent to the amygdala
in the medial temporal lobe, likewise showed GM
increase after 3 wk of treatment. Structural pathology in
the entorhinal cortex volume is frequently observed in
schizophrenia patients (Pearlson et al., 1997; Joyal et al.,
2002; Turetsky et al., 2003; Prasad et al., 2004; Baiano
et al., 2008) and assumed to contribute to psychopath-
ology and cognitive disturbances of the disease (Baiano
et al., 2008). Structural alterations in the entorhinal cortex
are not likely to reﬂect disease chronicity or exposure
to antipsychotics, but are associated with positive symp-
toms (Prasad et al., 2004). The concomitance of GM
changes in the entorhinal cortex and signiﬁcant changes
on the PANSS positive subscale in the present sample
of ﬁrst-episode schizophrenia patients is in line with
this observation.
VBM is not capable of disclosing the mechanism of
the underlying longitudinal GM changes. In general, an
increase in cell size, neural or glial cell genesis, spine den-
sity or even changes in blood ﬂow or interstitial ﬂuid
have been discussed as a basis for GM increases (May
et al., 2006). On a molecular level, D2 receptor blockade
induces reversible remodeling of GM in cortical–striatal
circuits within hours (Tost et al., 2010). Such synaptic
remodeling, as well as neuronal growth, are affected
by immediate effector proteins such as brain-derived neu-
rotrophic factor (BDNF) (Tost et al., 2010). Quetiapine has
been shown to upregulate the glial cell line-derived neu-
rotrophic factor (GDNF) (Di Benedetto et al., 2012) and
BDNF (Xu et al., 2002; Fumagalli et al., 2004; Luo et al.,
2005; Park et al., 2006). More speciﬁcally, quetiapine pro-
motes neuroplasticity by inducing upregulation of BDNF
expression in hippocampal regions in rats (Xu et al., 2002;
Fumagalli et al., 2004; Luo et al., 2005; Park et al., 2006).
This effect seems to be drug-speciﬁc and was not
observed with the conventional antipsychotic agent halo-
peridol (Fumagalli et al., 2004). BDNF contributes to the
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etiology of schizophrenia and is modulated by neurolep-
tic treatment (Angelucci et al., 2005; Szeszko et al., 2005);
schizophrenia in turn is related to GM abnormalities in
amygdaloparahippocampal regions (Chan et al., 2011).
Moreover, deﬁcits in prepulse inhibition of startle,
which is also impaired in schizophrenia, are reversed by
quetiapine in rats with lesions of the basolateral amyg-
dala (Shoemaker et al., 2003), even though this effect
was not observed for short-term quetiapine treatment in
schizophrenia patients (Molina et al., 2011). Recently,
there is growing empirical support for BDNF-dependent
modulation of neural plasticity in the amygdala
(Cowansage et al., 2010). Alternative explanations for
the observed volume increases, such as acute cell swel-
ling, e.g. through quetiapine-related mitochondrial dam-
age (Modica-Napolitano et al., 2003) leading to increased
osmotic pressure, cannot be excluded, but seem unlikely.
Thus, our ﬁnding of prominent longitudinal increase
of amygdala GM correlating with quetiapine plasma
levels supports the notion that quetiapine-induced neuro-
plasticity is mediated by neurotrophic factors.
One limitation of this study is the modest sample
size. Therefore, we cannot exclude effects other than the
reported ones being overlooked. In this regard, the rela-
tively high number of drop outs (N=23) has also to be
considered. However, only a minor number of patients
(N=5) had to be excluded due to reasons that might be
seen in the context of quetiapine treatment (comedication,
side effects, noncompliance). Most drop-outs were due to
the fact that the suspected diagnosis of schizophrenia
could not be conﬁrmed. In this context, it has to be con-
sidered that no structured diagnostic instruments were
applied at the time of screening. The subsequent
application of strict diagnostic criteria according to the
ICD-10, however, ensured that all included patients in
fact suffered from a ﬁrst episode of schizophrenia. At
the same time, the sample was not restricted to a parti-
cularly compliant sample or to treatment responders.
However, it should be kept in mind that the ﬁndings
are restricted to unmedicated ﬁrst-episode patients.
Future studies should investigate whether the reported
GM changes can also be observed in chronic patients.
Another limitation of the study is the lack of a placebo
control. However, the main ﬁnding of the study, the
correlation between GM increase in the amygdalo-
hippocampal complex and quetiapine plasma levels, is
unaffected by the lack of a placebo control. Nevertheless,
it cannot be excluded that the observed longitudinal
GM changes are independent of quetiapine treatment,
even if this seems rather unlikely. Last but not least, it
has to be considered that we do not have information
on socioeconomic status, education levels or (premorbid)
IQ estimates. Although a previous VBM study (Haier
et al., 2004) suggests that at least general intelligence
is not correlated with GM volume in the amygdalo-
hippocampal region, these variables might have affected
the results of the group comparison.
In summary, the present results provide evidence
for a quetiapine-related increase of GM volume in the
amygdalohippocampal complex in patients suffering
from ﬁrst-episode schizophrenia, and show that this in-
crease is predicted by quetiapine plasma levels but not
by quetiapine doses. These neuroanatomical changes
are already detectable after 21 d. These ﬁndings suggest
that drug-induced structural neuroplasticity in schizo-
phrenia can occur quickly, and is likely to depend on
pharmacokinetics.
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